Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?

References

• Koye DN, Magliano DJ, Nelson RG, et al. The global Epidemiology of diabetes and kidney disease. Adv Chronic Kidney Dis. 2018 Mar;25(2):121–132. doi: 10.1053/j.ackd.2017.10.011
   PubMed Web of Science ®Google Scholar
• Low SK, Sum CF, Yeoh LY, et al. Prevalence of chronic kidney disease in adults with type 2 diabetes mellitus. Ann Acad Med Singap. 2015 May;44(5):164–171. doi: 10.47102/annals-acadmedsg.V44N5p164
   PubMed Web of Science ®Google Scholar
• Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015 Jul 30;1(1):15018. doi: 10.1038/nrdp.2015.18
   PubMedGoogle Scholar
• Kim S, Jeon J, Lee YJ, et al. Depression is a main determinant of health-related quality of life in patients with diabetic kidney disease. Sci Rep. 2022 Jul 16;12(1):12159. doi: 10.1038/s41598-022-15906-z
   PubMed Web of Science ®Google Scholar
• Mullins CD, Pantalone KM, Betts KA, et al. CKD Progression and Economic Burden in Individuals With CKD Associated With Type 2 Diabetes. Kidney Med. 2022 Nov;4(11):100532. doi: 10.1016/j.xkme.2022.100532
   PubMedGoogle Scholar
• Meraya AM, Alwhaibi M. Health related quality of life and healthcare utilization among adults with diabetes and kidney and eye complications in the United States. Health Qual Life Outcomes. 2020 Mar 30;18(1):85. doi: 10.1186/s12955-020-01336-w
   PubMed Web of Science ®Google Scholar
• Lim GJ, Liu YL, Low S, et al. Medical costs associated with severity of chronic kidney disease in type 2 diabetes mellitus in Singapore. Ann Acad Med Singap. 2020;49(10):731–741. doi: 10.47102/annals-acadmedsg.202032
   PubMed Web of Science ®Google Scholar
• Nathan DM, Genuth S, Diabetes Control and Complications Trial Research Group, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med.1993 Sep 30;329(14):977–986.
   PubMed Web of Science ®Google Scholar
• Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of diabetes Interventions and complications (EDIC) study. JAMA. [2003 Oct 22];290(16):2159–2167. doi: 10.1001/jama.290.16.2159
   PubMed Web of Science ®Google Scholar
• DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the diabetes control and complications trial and Epidemiology of diabetes Interventions and complications study. Lancet Diabetes Endocrinol. 2014 Oct;2(10):793–800. doi: 10.1016/S2213-8587(14)70155-X
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853. doi: 10.1016/S0140-6736(98)07019-6
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577–1589. doi: 10.1056/NEJMoa0806470
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, ADVANCE Collaborative Group, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med.2008 Jun 12;358(24):2560–2572.
   PubMed Web of Science ®Google Scholar
• Wong MG, Perkovic V, Chalmers J, et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care. 2016 May;39(5):694–700. doi: 10.2337/dc15-2322
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 Jan 8;360(2):129–139. doi: 10.1056/NEJMoa0808431
   PubMed Web of Science ®Google Scholar
• Reaven PD, Emanuele NV, Wiitala WL, et al. Intensive glucose control in patients with type 2 diabetes - 15-year follow-up. N Engl J Med. 2019 Jun 6;380(23):2215–2224. doi: 10.1056/NEJMoa1806802
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Action to Control Cardiovascular Risk in Diabetes Study Group, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med.2008 Jun 12;358(24):2545–2559.
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group. Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes. Diabetes Care. 2016 May;39(5):701–708. doi: 10.2337/dc15-2283
   PubMed Web of Science ®Google Scholar
• Kloecker DE, Davies MJ, Pitocco D, et al. Intensive glucose control and recurrent cardiovascular events: 14-year follow-up investigation of the ACCORDION study. Diabetes Metab Res Rev. 2023 Jul;39(5):e3634. doi: 10.1002/dmrr.3634
   PubMed Web of Science ®Google Scholar
• Mottl AK, Buse JB, Ismail-Beigi F, et al. Long-term effects of intensive glycemic and blood pressure control and fenofibrate use on kidney outcomes. Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1693–1702. doi: 10.2215/CJN.06200518
   PubMed Web of Science ®Google Scholar
• Coca SG, Ismail-Beigi F, Haq N, et al. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med. 2012 May 28;172(10):761–769. doi: 10.1001/archinternmed.2011.2230
   PubMedGoogle Scholar
• Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative study group. N Engl J Med. 1993 Nov 11;329(20):1456–1462. doi: 10.1056/NEJM199311113292004
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep 20;345(12):861–869. doi: 10.1056/NEJMoa011161
   PubMed Web of Science ®Google Scholar
• Chen R, Suchard MA, Krumholz HM, et al. Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension. 2021 Sep;78(3):591–603. doi: 10.1161/HYPERTENSIONAHA.120.16667
   PubMed Web of Science ®Google Scholar
• Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015 May 23;385(9982):2047–2056. doi: 10.1016/S0140-6736(14)62459-4
   PubMed Web of Science ®Google Scholar
• Catala-Lopez F, Macias Saint-Gerons D, Gonzalez-Bermejo D, et al. Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses. PLOS Med. 2016 Mar;13(3):e1001971. doi: 10.1371/journal.pmed.1001971
   PubMed Web of Science ®Google Scholar
• Wang K, Hu J, Luo T, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis. Kidney Blood Press Res. 2018;43(3):768–779. doi: 10.1159/000489913
   PubMed Web of Science ®Google Scholar
• Qiao Y, Shin JI, Chen TK, et al. Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate. JAMA Intern Med. 2020 May 1;180(5):718–726. doi: 10.1001/jamainternmed.2020.0193
   PubMed Web of Science ®Google Scholar
• Bhandari S, Mehta S, Khwaja A, et al. Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med. 2022 Dec 1;387(22):2021–2032. doi: 10.1056/NEJMoa2210639
   PubMed Web of Science ®Google Scholar
• Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013 Nov 14;369(20):1892–1903. doi: 10.1056/NEJMoa1303154
   PubMed Web of Science ®Google Scholar
• Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000 Dec 9;321(7274):1440–1444. doi: 10.1136/bmj.321.7274.1440
   PubMedGoogle Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295–2306. doi: 10.1056/NEJMoa1811744
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation. 2019 Aug 27;140(9):739–750. doi: 10.1161/CIRCULATIONAHA.119.042007
   PubMed Web of Science ®Google Scholar
• Sarraju A, Li J, Cannon CP, et al. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: results from the CREDENCE trial. Am Heart J. 2021 Mar;233:141–148.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020 Oct 8;383(15):1436–1446. doi: 10.1056/NEJMoa2024816
   PubMed Web of Science ®Google Scholar
• Wheeler DC, Stefansson BV, Jongs N, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021 Jan;9(1):22–31. doi: 10.1016/S2213-8587(20)30369-7
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Sjostrom CD, Jongs N, et al. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. Eur Heart J. 2021 Mar 31;42(13):1216–1227. doi: 10.1093/eurheartj/ehab094
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Cherney D, Postmus D, et al. A pre-specified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney Int. 2022 Jan;101(1):174–184. doi: 10.1016/j.kint.2021.09.005
   PubMed Web of Science ®Google Scholar
• Herrington WG, Staplin N, The EMPA-KIDNEY Collaborative Group, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med.2023 Jan 12;388(2):117–127.
   PubMed Web of Science ®Google Scholar
• Forbes AK, Suckling RJ, Hinton W, et al. Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: a systematic review and meta-analysis of observational studies. Diab Obes Metab. 2023 Aug;25(8):2310–2330. doi: 10.1111/dom.15111
   PubMed Web of Science ®Google Scholar
• Liu AYL, Low S, Yeoh E, et al. A real-world study on SGLT2 inhibitors and diabetic kidney disease progression. Clin Kidney J. 2022 Jul;15(7):1403–1414. doi: 10.1093/ckj/sfac044
   PubMed Web of Science ®Google Scholar
• Ceriello A, Lucisano G, Prattichizzo F, et al. The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes. Lancet Reg Health Eur. 2023 Aug;31:100666.
   PubMedGoogle Scholar
• Mima A. Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets. J Diabetes Res. 2013;2013:248563. doi: 10.1155/2013/248563
   PubMed Web of Science ®Google Scholar
• Mima A. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease. J Diabetes Complications. 2018 Jul;32(7):720–725. doi: 10.1016/j.jdiacomp.2018.04.011
   PubMed Web of Science ®Google Scholar
• Tuttle KR. Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors. J Clin Invest. 2023 Mar 1;133(5). doi: 10.1172/JCI167700
   Web of Science ®Google Scholar
• Mima A. Mitochondria-targeted drugs for diabetic kidney disease. Heliyon. 2022 Feb;8(2):e08878. doi: 10.1016/j.heliyon.2022.e08878
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021 Jan 14;384(2):117–128. doi: 10.1056/NEJMoa2030183
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021 Jan 14;384(2):129–139. doi: 10.1056/NEJMoa2030186
   PubMed Web of Science ®Google Scholar
• Cherney DZI, Ferrannini E, Umpierrez GE, et al. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease. Diab Obes Metab. 2023 Jun;25(6):1646–1657. doi: 10.1111/dom.15019
   PubMed Web of Science ®Google Scholar
• Stougaard EB, Rossing P, Vistisen D, et al. Sotagliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 risk Engine in adults with type 1 diabetes. Diab Obes Metab. 2023 Jul;25(7):1874–1882. doi: 10.1111/dom.15047
   PubMed Web of Science ®Google Scholar
• Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. [2022 Nov 19];400(10365):1788–1801. doi: 10.1016/S0140-6736(22)02074-8
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016 Jul 28;375(4):311–322. doi: 10.1056/NEJMoa1603827
   PubMed Web of Science ®Google Scholar
• Mann JFE, Orsted DD, Brown-Frandsen K, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017 Aug 31;377(9):839–848. doi: 10.1056/NEJMoa1616011
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016 Nov 10;375(19):1834–1844. doi: 10.1056/NEJMoa1607141
   PubMed Web of Science ®Google Scholar
• Tuttle KR, Bosch-Traberg H, Cherney DZI, et al. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. Kidney Int. 2023 Apr;103(4):772–781. doi: 10.1016/j.kint.2022.12.028
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018 Oct 27;392(10157):1519–1529. doi: 10.1016/S0140-6736(18)32261-X
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):121–130. doi: 10.1016/S0140-6736(19)31149-3
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):131–138. doi: 10.1016/S0140-6736(19)31150-X
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021 Sep 2;385(10):896–907. doi: 10.1056/NEJMoa2108269
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015 Dec 3;373(23):2247–2257. doi: 10.1056/NEJMoa1509225
   PubMed Web of Science ®Google Scholar
• Muskiet MHA, Tonneijck L, Huang Y, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018 Nov;6(11):859–869. doi: 10.1016/S2213-8587(18)30268-7
   PubMed Web of Science ®Google Scholar
• Holman RR, Bethel MA, Mentz RJ, et al. Effects of Once-weekly Exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017 Sep 28;377(13):1228–1239. doi: 10.1056/NEJMoa1612917
   PubMed Web of Science ®Google Scholar
• Bethel MA, Mentz RJ, Merrill P, et al. Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. Diabetes Care. 2020 Feb;43(2):446–452. doi: 10.2337/dc19-1065
   PubMed Web of Science ®Google Scholar
• Ma J, Cooper ME. Potential cardiorenal benefits of efpeglenatide in diabetes. Nat Rev Nephrol. 2021 Nov;17(11):708–709. doi: 10.1038/s41581-021-00475-7
   PubMed Web of Science ®Google Scholar
• Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019 Aug 29;381(9):841–851. doi: 10.1056/NEJMoa1901118
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Sattar N, Pavo I, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022 Nov;10(11):774–785. doi: 10.1016/S2213-8587(22)00243-1
   PubMed Web of Science ®Google Scholar
• Lin Y, Wang TH, Tsai ML, et al. The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease. Cardiovasc Diabetol. 2023 Mar 17;22(1):60. doi: 10.1186/s12933-023-01793-9
   PubMed Web of Science ®Google Scholar
• Chen JJ, Wu CY, Jenq CC, et al. Association of glucagon-like peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease. JAMA Netw Open. 2022 Mar 1;5(3):e221169. doi: 10.1001/jamanetworkopen.2022.1169
   PubMed Web of Science ®Google Scholar
• Rossing P, Baeres FMM, Bakris G, et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023 Jan 18;38(9):2041–2051. doi: 10.1093/ndt/gfad009
   PubMed Web of Science ®Google Scholar
• Bjornstad P, Cherney D, Lawson J, et al. MO399: remodel: a mechanistic trial evaluating the effects of semaglutide on the kidneys in people with type 2 diabetes and chronic kidney disease. Nephrol Dialysis Transplantation. 2022;37(Supplement_3). doi: 10.1093/ndt/gfac070.013
   Google Scholar
• McGuire DK, Busui RP, Deanfield J, et al. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: design and baseline characteristics of SOUL, a randomized trial. Diab Obes Metab. 2023 Jul;25(7):1932–1941. doi: 10.1111/dom.15058
   PubMed Web of Science ®Google Scholar
• Chung EY, Ruospo M, Natale P, et al.Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney diseaseCochrane Database Syst Rev2020 Oct 2710 CD0070041010.1002/14651858.CD007004.pub4
   Google Scholar
• Whitlock R, Leon SJ, Manacsa H, et al. The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant. 2023 Jun 12. doi: 10.1093/ndt/gfad101
   Web of Science ®Google Scholar
• Kolkhof P, Barfacker L. 30 YEARS of the MINERALOCORTICOID RECEPTOR: mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017 Jul;234(1):T125–T140. doi: 10.1530/JOE-16-0600
   PubMed Web of Science ®Google Scholar
• Oiwa A, Hiwatashi D, Takeda T, et al. Efficacy and safety of low-dose spironolactone for chronic kidney disease in type 2 diabetes. J Clin Endocrinol Metab. 2023 Aug 18;108(9):2203–2210. doi: 10.1210/clinem/dgad144
   PubMed Web of Science ®Google Scholar
• Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021 Jan 7;42(2):152–161. doi: 10.1093/eurheartj/ehaa736
   PubMed Web of Science ®Google Scholar
• Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020 Dec 3;383(23):2219–2229. doi: 10.1056/NEJMoa2025845
   PubMed Web of Science ®Google Scholar
• Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with Finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021 Dec 9;385(24):2252–2263. doi: 10.1056/NEJMoa2110956
   PubMed Web of Science ®Google Scholar
• Ito S, Kashihara N, Shikata K, et al. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial. Clin J Am Soc Nephrol. 2020 Dec 7;15(12):1715–1727. doi: 10.2215/CJN.06870520
   PubMed Web of Science ®Google Scholar
• Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022 Feb 10;43(6):474–484. doi: 10.1093/eurheartj/ehab777
   PubMed Web of Science ®Google Scholar
• Green JB, Mottl AK, Bakris G, et al. Design of the COmbinatioN effect of FInerenone and EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR endpoint study (CONFIDENCE). Nephrol Dial Transplant. 2023 Mar 31;38(4):894–903. doi: 10.1093/ndt/gfac198
   PubMed Web of Science ®Google Scholar
• Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide Once weekly in patients with type 2 diabetes. N Engl J Med. 2021 Aug 5;385(6):503–515. doi: 10.1056/NEJMoa2107519
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023 Jun 26;402(10401):529–544. doi: 10.1016/S0140-6736(23)01053-X
   PubMed Web of Science ®Google Scholar
• Conceicao-Furber E, Coskun T, Sloop KW, et al. Is glucagon receptor activation the thermogenic solution for treating obesity? Front Endocrinol. 2022;13:868037. doi: 10.3389/fendo.2022.868037
   PubMed Web of Science ®Google Scholar
• Charron MJ, Vuguin PM. Lack of glucagon receptor signaling and its implications beyond glucose homeostasis. J Endocrinol. 2015 Mar;224(3):R123–30. doi: 10.1530/JOE-14-0614
   PubMed Web of Science ®Google Scholar
• Bankir L, Bouby N, Blondeau B, et al. Glucagon actions on the kidney revisited: possible role in potassium homeostasis. Am J Physiol Renal Physiol. 2016 Aug 1;311(2):F469–86. doi: 10.1152/ajprenal.00560.2015
   PubMed Web of Science ®Google Scholar
• Romero CA, Orias M, Weir MR. Novel RAAS agonists and antagonists: clinical applications and controversies. Nat Rev Endocrinol. 2015 Apr;11(4):242–252. doi: 10.1038/nrendo.2015.6
   PubMed Web of Science ®Google Scholar
• Bogman K, Schwab D, Delporte ML, et al. Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2). Hypertension. 2017 Jan;69(1):189–196. doi: 10.1161/HYPERTENSIONAHA.116.07716
   PubMed Web of Science ®Google Scholar
• Freeman MW, Halvorsen YD, Marshall W, et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med. 2023 Feb 2;388(5):395–405. doi: 10.1056/NEJMoa2213169
   PubMed Web of Science ®Google Scholar
• Tuttle K, Rossing P, Cronin L, et al. #3318 phase ii dose-selection, randomised Double-blind trial of the Asi, bi 690517, alone and in combination with Empa in people with ckd. Nephrol Dialysis Transplantation. 2023;38(Supplement_1). doi: 10.1093/ndt/gfad063c_3318
   PubMedGoogle Scholar
• Haynes R, Judge PK, Staplin N, et al. Effects of sacubitril/valsartan versus Irbesartan in patients with chronic kidney disease. Circulation. 2018 Oct 9;138(15):1505–1514. doi: 10.1161/CIRCULATIONAHA.118.034818
   PubMed Web of Science ®Google Scholar
• Peikert A, Vaduganathan M, Mc Causland F, et al. Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF. Eur J Heart Fail. 2022 May;24(5):794–803. doi: 10.1002/ejhf.2450
   PubMed Web of Science ®Google Scholar
• Zhou W, Yang X, Jin J, et al. The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol. 2023 May 17. doi: 10.1007/s11255-023-03599-w
   Web of Science ®Google Scholar
• Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec 6;367(23):2204–2213. doi: 10.1056/NEJMoa1208799
   PubMed Web of Science ®Google Scholar
• Ito S, Kagawa T, Saiki T, et al. Efficacy and safety of imarikiren in patients with type 2 diabetes and microalbuminuria: a randomized, controlled trial. Clin J Am Soc Nephrol. 2019 Mar 7;14(3):354–363. doi: 10.2215/CJN.07720618
   PubMed Web of Science ®Google Scholar
• Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 2008 Apr;93(4):1143–1152. doi: 10.1210/jc.2007-1817
   PubMed Web of Science ®Google Scholar
• Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010 Mar;21(3):527–535. doi: 10.1681/ASN.2009060593
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019 May 11;393(10184):1937–1947. doi: 10.1016/S0140-6736(19)30772-X
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Kohan DE, de Zeeuw D. New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction. Kidney Int. 2021 Feb;99(2):346–349. doi: 10.1016/j.kint.2020.09.026
   PubMed Web of Science ®Google Scholar
• Fong TM, Heymsfield SB. Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions. Int J Obes (Lond). 2009 Sep;33(9):947–955. doi: 10.1038/ijo.2009.132
   PubMed Web of Science ®Google Scholar
• Francois H, Lecru L. The role of cannabinoid receptors in renal diseases. Curr Med Chem. 2018;25(7):793–801. doi: 10.2174/0929867324666170911170020
   PubMed Web of Science ®Google Scholar
• Barutta F, Corbelli A, Mastrocola R, et al. Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes. 2010 Apr;59(4):1046–1054. doi: 10.2337/db09-1336
   PubMed Web of Science ®Google Scholar
• Jacquot L, Pointeau O, Roger-Villeboeuf C, et al. Therapeutic potential of a novel peripherally restricted CB1R inverse agonist on the progression of diabetic nephropathy. Front Nephrol. 2023;3:3. doi: 10.3389/fneph.2023.1138416
   Google Scholar
• Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006 Feb 15;295(7):761–775. doi: 10.1001/jama.295.7.761
   PubMed Web of Science ®Google Scholar
• King A. Prevention: neuropsychiatric adverse effects signal the end of the line for rimonabant. Nat Rev Cardiol. 2010 Nov;7(11):602. doi: 10.1038/nrcardio.2010.148
   PubMedGoogle Scholar
• Tanase DM, Gosav EM, Anton MI, et al. Oxidative stress and NRF2/KEAP1/ARE pathway in diabetic kidney disease (DKD): new perspectives. Biomolecules. 2022 Sep 2;12(9):1227. doi: 10.3390/biom12091227
   PubMed Web of Science ®Google Scholar
• Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011 Jul 28;365(4):327–336. doi: 10.1056/NEJMoa1105351
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013 Dec 26;369(26):2492–2503. doi: 10.1056/NEJMoa1306033
   PubMed Web of Science ®Google Scholar
• Nangaku M, Takama H, Ichikawa T, et al. Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study. Nephrol Dial Transplant. 2023 May 4;38(5):1204–1216. doi: 10.1093/ndt/gfac242
   PubMed Web of Science ®Google Scholar
• Moon JS, Won KC, Kim M-J, et al. 821-P: randomized clinical trial on the renoprotective effect of CU01-10in patients with diabetic kidney disease (DKD). Diabetes. 2022;71(Supplement_1). doi: 10.2337/db22-821-P
   PubMedGoogle Scholar
• Wen L, Wei Q. ASK1 inhibitor in chronic kidney disease therapy: from bench to bedside. Kidney360. 2022 Jul 28;3(7):1128–1131. doi: 10.34067/KID.0002562022
   PubMedGoogle Scholar
• Chertow GM, Pergola PE, Chen F, et al. Effects of selonsertib in patients with diabetic kidney disease. J Am Soc Nephrol. 2019 Oct;30(10):1980–1990. doi: 10.1681/ASN.2018121231
   PubMed Web of Science ®Google Scholar
• Chen WY, Li LC, Yang JL. Emerging roles of IL-33/ST2 axis in renal diseases. Int J Mol Sci. 2017 Apr 7;18(4):783. doi: 10.3390/ijms18040783
   PubMed Web of Science ®Google Scholar
• England E, Rees DG, Scott IC, et al. Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction. Sci Rep. 2023 Jun 17;13(1):9825. doi: 10.1038/s41598-023-36642-y
   PubMed Web of Science ®Google Scholar
• Wang A-M, Mallamaci F, Zoccali C. What is central to renal nutrition: protein or sodium intake? Clin Kidney J;2023. doi: 10.1093/ckj/sfad151
   Web of Science ®Google Scholar
• Bellizzi V, Garofalo C, Ferrara C, et al. Ketoanalogue supplementation in patients with non-dialysis diabetic kidney disease: a systematic review and meta-analysis. Nutrients. 2022 Jan 19;14(3):441. doi: 10.3390/nu14030441
   PubMed Web of Science ®Google Scholar
• Yen CL, Fan PC, Chen JJ, et al. Ketoanalogues supplemental low protein diet safely decreases short-term risk of dialysis among CKD stage 4 patients. Nutrients. 2022 Sep 28;14(19):4020. doi: 10.3390/nu14194020
   PubMed Web of Science ®Google Scholar
• Lin JR, Wang ZT, Sun JJ, et al. Gut microbiota and diabetic kidney diseases: pathogenesis and therapeutic perspectives. World J Diabetes. 2022 Apr 15;13(4):308–318. doi: 10.4239/wjd.v13.i4.308
   PubMed Web of Science ®Google Scholar
• Okumura M, Imanishi M, Okamura M, et al. Role for thromboxane A2 from glomerular thrombi in nephropathy with type 2 diabetic rats. Life Sci. 2003 May 2;72(24):2695–2705. doi: 10.1016/S0024-3205(03)00180-2
   PubMed Web of Science ®Google Scholar
• Nagatani Y, Higashino T, Kinoshita K, et al. Thromboxane A(2) receptor antagonist (ONO-8809) attenuates renal disorders caused by salt overload in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 2021 Oct;48(10):1391–1401. doi: 10.1111/1440-1681.13543
   PubMed Web of Science ®Google Scholar